Superior outcomes associated with complete response in newly diagnosed multiple myeloma patients treated with nonintensive therapy: analysis of the phase 3 VISTA study of bortezomib plus melphalan-prednisone versus melphalan-prednisone
Year: 2010
Type: article
Source: Blood
Authors: Jean-Luc Harousseau, Antonio Palumbo, Paul G. Richardson, Rudolf Schlag, Meletios A. Dimopoulos, Ofer Shpilberg, Martin Kropff, Alain Kentos, Michele Cavo, Anatoly Golenkov, Mieczyslaw Komarnicki, Maria-Victoria Mateos, Dixie-Lee Esseltine, Andrew Cakana, Kevin Liu, William Deraedt, Helgi van de Velde, Jesús F. San Miguel
Institutions: University of Turin, Dana-Farber Cancer Institute, National and Kapodistrian University of Athens, Rabin Medical Center, University of Münster, University of Bologna, Poznan University of Medical Sciences, Consejo Superior de Investigaciones Científicas, Universidad de Salamanca, Centro de Investigación del Cáncer, Takeda Oncology (United States), Johnson & Johnson (United Kingdom), Janssen Research & Development (United States), Janssen (Belgium)
Language: English
Subfield: Hematology
Field: Medicine
Domain: Health Sciences
Open Access status: bronze
Funder: Takeda Oncology
OpenAlex ID: W2062373072
